Biotechnology | COVID-19 | FDA | NIH | Therapeutics
Medigen Vaccines obtained TFDA phase 2 IND approval for COVID19 vaccine
On Dec. 30, 2020, Medigen Vaccine Biologics announced that it had obtained TFDA Phase 2 IND approval of…
NIH neuroscientists isolated promising mini antibodies against COVID-19 from a llama
On Dec. 22, 2020, the NIH researchers announced they had isolated a set of promising, tiny antibodies, or…
NIH ACTIV Trial of blood thinners paused enrollment of critically ill COVID-19 patients
On Dec. 22, 2020, the NIH researchers announced that three clinical trial platforms working together to test the…
NIH announced support of radical approaches to nationwide COVID-19 testing and surveillance
On Dec. 21, 2020, the NIH announced that it had awarded over $107 million to support new, non-traditional…
NIH funded eight studies to uncover risk factors for COVID-19-related inflammatory syndrome in children
On Dec. 21, 2020, the NIH announced that it had awarded eight research grants to develop approaches for…
Reston Ebolavirus spreads efficiently in pigs
On Dec. 21, 2020, the U.S. National Institutes of Health (NIH) announced a study published in the Proceedings…
Meridian received NIH award for supporting rapid development of Revogeneﾮ molecular test for SARS-CoV-2
On Dec. 16, 2020, Meridian Bioscience announced that it had been awarded funding in the amount of approximately…
Moderna updated on clinical development and production of Its COVID-19 vaccine candidate
On Dec. 3, 2020, Moderna announced in a letter to the editor published in the New England Journal…
NIH announced restructured HIV clinical trials networks
On Nov. 30, 2020, The National Institute of Allergy and Infectious Diseases (NIAID) announced the clinical investigators and…
Commonly used antibiotic showed promise for combating Zika infections
On Nov. 24, 2020, preclinical study by the National Institutes of Health (NIH) suggested FDA-approved tetracycline-based antibiotics may…
NIH expanded research to improve COVID-19 testing among underserved and vulnerable populations
On Nov. 20, 2020, the National Institutes of Health (NIH) awarded nearly $45 million to expand the research…
Study of ‘exceptional responders’ yields clues to cancer and potential treatments
On Nov. 19, 2020, in a comprehensive analysis of patients with cancer who had exceptional responses to therapy,…
NIH to fund research of racial disparities in pregnancy-related complications and deaths
On Nov. 17, 2020, the NIH announced funding of new research examining racial and ethnic disparities in pregnancy-related…
Celdara Medical secured SBIR funding to develop an adjuvanted universal flu vaccine
On Nov. 17, 2020, Celdara Medical announced that the National Institute of Allergy and Infectious Disease (NIAID) of…
Moderna’s COVID-19 vaccine candidate met primary endpoint in first interim analysis of phase 3 COVE study
On Nov. 15, 2020, an independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of…
Moderna completed case accrual for first planned interim analysis of mRNA vaccine against COVID-19
On Nov. 11, 2020, Moderna announced that it had completed case accrual for the first interim analysis of…
Biotechnology | HIV | NIH | Therapeutics
Long-acting injectable drug prevented HIV in cisgender women
On Nov. 9, 2020, the NIH reported that a pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form…
Hydroxychloroquine does not benefit adults hospitalized with COVID-19
On Nov. 9, 2020, a National Institutes of Health (NIH) clinical trial evaluating the safety and effectiveness of…
Single-cell study of Ebola highlighted virus’s lethal maneuvers
On Nov. 6, 2020, in a study published in Cell, the researchers identified antiviral defense genes that the…
Biotechnology | COVID-19 | Medicine | NIH | Therapeutics | Vaccine
Medigen Vaccines and NIHE partnered to develop COVID-19 vaccine in Vietnam
On Nov. 3, 2020, Medigen Vaccine Biologics (MVC) and the National Institute of Hygiene and Epidemiology (NIHE), a…
Final NIH policy for data management and sharing released
On Oct. 29, 2020, the National Institutes of Health (NIH) announed that it will begin requiring most of…
NIH scientists discovered key pathway in lysosomes that coronaviruses use to exit cells
On Oct. 28, 2020, researchers at the NIH announced that they had discovered a biological pathway that the…
Postpartum depression may persist three years after giving birth
On Oct. 27, 2020, a National Institutes of Health (NIH) study of 5,000 women found that approximately 1…
Biotechnology | Diagnostics | Disease | Genomics | NIH | Therapeutics
Scientists used clues in the human genome to discover new inflammatory syndrome
On Oct. 27, 2020, researchers from the National Institutes of Health (NIH) announced they had discovered a new…
Plant compound reduced cognitive deficits in mouse model of Down syndrome
On Oct. 23, 2020, NIH researchers reported that the plant compound apigenin improved the cognitive and memory deficits…
Final report confirmed remdesivir benefits for COVID-19
On Oct. 20, 2020, the NIH announced that the researchers had completed the Adaptive COVID-19 Treatment Trial (ACTT-1),…
PerkinElmer immunoassay identiied therapeutic compounds capable of disrupting the SARS-CoV-2 spike protein/ACE2 interaction
On Oct. 20, 2020, PerkinElmer announced that a research team at the National Center for Advancing Translational Sciences…
Study discovered gene that helps us know when itﾒs time to urinate
On Oct. 19, 2020, researchers annoounced they had discovered that a gene, called PIEZO2, may be responsible for…
NIH began large clinical trial to test immune modulators for treatment of COVID-19
On Oct. 16, 2020, the NIH launched an adaptive Phase 3 clinical trial to evaluate the safety and…
Biotechnology | COVID-19 | NIH | Therapeutics
NIH launched its ACTIV-5 ‘Big Effect Trial’ evaluating Humanigen’s Lenzilumabas potential COVID-19 therapy
On Oct. 13, 2020, Humanigen announced that the National Institute of Allergy and Infectious Diseases (NIAID), had launched…